Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention
- 235 Downloads
This commentary relates to a paper on the development and piloting of a risk management intervention in Portuguese community pharmacy, based on validated preventable drug-related morbidity indicators. In the paper we presented the research programme and implications for future evaluation. However, we believe that the intervention may be seen as important for patient safety without further evaluation. Therefore in this commentary we discuss considerations for service roll-out, by revisiting some issues already presented and by introducing aspects such as service definition and remuneration. We argue that in the absence of service remuneration, redesign of care processes through IT support and inter-professional collaboration, and coaching to encourage the aforementioned efforts it is unlikely that the proposed risk management intervention will succeed in preventing drug-related morbidity.
KeywordsCommunity pharmacy Indicators Patient safety Portugal Preventable drug-related morbidity
Conflicts of interest
- 1.Guerreiro MP, Martins AP, Cantrill JA. Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention. Int J Clin Pharm. 2012; published on-line. doi: 10.1007/s11096-012-9625-3.
- 3.Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–19.Google Scholar
- 5.Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Safety. 2007;16:55–64.CrossRefGoogle Scholar
- 9.Costa FA, Duggan C, Bates I. Validation of a survey tool for use in cross-cultural studies. Pharmacy Practice. 2008;6:121–7.Google Scholar
- 11.MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP 2003; 9:134–41.Google Scholar
- 12.Government Decree no. 112/2011, 29th November (Decreto-Lei no 112/2011, 29 de Novembro).Google Scholar
- 14.Ministerial Order no. 301/2008, 18th April (Portaria no 301/2008, de 18 de Abril).Google Scholar
- 16.Shah NR, Seger AC, Seger D, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK. Improving acceptance of computerized prescribing alerts in ambulatory care. JAMIA 2006; 13: 5–11.Google Scholar
- 17.Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606.Google Scholar
- 18.Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs in innovative clinical services—a conceptual model. J Soc Adm Pharm. 1999;16:134–43.Google Scholar
- 21.Schnipper JL, Rothschild JM. Improving medication safety. Lancet. 2012;379(9823):1278–80.Google Scholar